Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

abbvie_0

AbbVie reports 26% rise in Q3 revenues

October 30, 2015 Sales and Marketing AbbVie, Humira

AbbVie has announced stronger-than-anticipated Q3 financial results, its revenues increasing 26.2% on the same period last year to $5.944 billion, …
News
Phase III trial

FDA approves new therapy for pancreatic cancer

October 30, 2015 Medical Communications, Sales and Marketing FDA, Pancreatic cancer

The FDA has approved drug a pancreatic cancer drug, Onivyde, which has produced significant overall survival rates in an international …
News
valeant_logo

Valeant drops Philidor after prescription fraud row

October 30, 2015 Medical Communications, Sales and Marketing Valeant

Valeant has announced that it is ‘severing all ties with Philidor’, the specialty pharmacy at the heart of recent controversy surrounding …
News
Constella

Allergan acquires rights to pioneering IBS treatment from Almirall

October 29, 2015 Medical Communications, Sales and Marketing Allergan, Constella, IBS, linaclotide

Allergan and its commercialisation partner Ironwood Pharmaceuticals have announced that Allergan has acquired the rights to Constella.The companies have acquired …
News
Coins

ANALYSIS: The challenges of forecasting biosimilar sales across Europe

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts

The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …
Feature
Yervoy

FDA approves Bristol-Myers Squibb’s skin cancer drug

October 29, 2015 Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma

The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …
News
novo_nordisk

Novo Nordisk posts strong nine-month results

October 29, 2015 Sales and Marketing Novo Nordisk, insulin

Novo Nordisk has exceeded market expectations in its nine-month financial results, reporting a 51% increase in operating profit and 33% …
News

Bayer posts strong earnings growth

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing

Sales across the Bayer group rose by 1.9% in the third quarter of 2015 to €11 billion, according the company’s …
News
allergan_pfizer_logos

Pfizer in ‘friendly’ merger talks with Allergan

October 29, 2015 Sales and Marketing Actavis, Allergan, Pfizer, Teva

Pfizer is in talks with Allergan over what could be the largest takeover deal in an already record-breaking year, it …
News
jose_joe_almeida

Baxter names José Almeida chairman and chief executive

October 29, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Joe Almeida, José Almeida, baxter

Baxter has named José (Joe) Almeida as the company’s new chairman and chief executive from January 1, 2016. Almeida will …
Appointment
imlygic_amgen

FDA approves first-in-class Amgen melanoma drug

October 28, 2015 Research and Development, Sales and Marketing Amgen, Imlygic, melonoma

The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …
News
Jinarc

Otsuka kidney drug earns first NICE nod

October 28, 2015 Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …
News
Merck image

Sales up at MSD while Keytruda hits survival target in late-stage trial

October 28, 2015 Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab

Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …
News
Sativex

Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015 Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
News
BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015 Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …
Feature
The Gateway to Local Adoption Series

Latest content

Trio become latest Symbiosis commercial additions

October 12, 2026

UK immunoglobulin supply faces growing pressure, report warns

October 12, 2026

How will biomarker-led diagnostics reshape respiratory medicine?

October 11, 2026

Five Facts about COPD

October 11, 2026

“That gap between innovation and delivery was what stood out to me most”

October 11, 2026